Seeking Alpha

Roche (RHHBY.PK -1.4%) has received premarket approval from the FDA for a new test to assess...

Roche (RHHBY.PK -1.4%) has received premarket approval from the FDA for a new test to assess patients for the cytomegalovirus. The fully automated process is the first FDA-approved laboratory test for use in quantifying the virus through DNA in human plasma specimens. Roche expects to begin shipping the new test kit in the U.S. in August.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs